Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Change in Account Payables (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Change in Account Payables for 8 consecutive years, with $815000.0 as the latest value for Q4 2024.

  • Quarterly Change in Account Payables rose 508.21% to $815000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2024, up 388.61% year-over-year, with the annual reading at -$1.1 million for FY2025, 149.57% down from the prior year.
  • Change in Account Payables hit $815000.0 in Q4 2024 for Solid Biosciences, down from $918000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.7 million in Q1 2023 to a low of -$5.9 million in Q4 2022.
  • Historically, Change in Account Payables has averaged -$301350.0 across 5 years, with a median of $210500.0 in 2022.
  • Biggest five-year swings in Change in Account Payables: tumbled 1136.14% in 2022 and later surged 3766.2% in 2023.
  • Year by year, Change in Account Payables stood at -$829000.0 in 2020, then soared by 168.76% to $570000.0 in 2021, then crashed by 1136.14% to -$5.9 million in 2022, then skyrocketed by 102.27% to $134000.0 in 2023, then soared by 508.21% to $815000.0 in 2024.
  • Business Quant data shows Change in Account Payables for SLDB at $815000.0 in Q4 2024, $918000.0 in Q3 2024, and $1.1 million in Q2 2024.